Pharmafile Logo
Pharmafocus logo
Advanced Search

pharma

Showing 15 posts of 2914 posts found.

Novartis’ Mayzent delays time wheelchair dependence by 4 years in secondary progressive multiple sclerosis

September 12, 2019
Research and Development ECTRIMS 2019, Mayzent, Novartis, multiple sclerosis, pharma

Novartis has taken the opportunity at the 2019 Congress of The European Committee for Treatment and Research in Multiple Sclerosis …

News
biogen_austria_238

Decade-long data support Biogen’s Tecfidera in relapsing multiple sclerosis

September 11, 2019
Research and Development Biogen, multiple sclerosis, pharma, tecfidera

Biogen has revealed new long-term data for Tecfidera (dimethyl fumarate), reinforcing the benefits of the therapy over a decade-long period …

News
opdivo_1_1

BMS unveils strong five-year efficacy data for Opdivo in lung cancer

September 11, 2019
Research and Development Bristol-Myers Squibb, Cancer, immunotherapy, lung cancer, pharma

Bristol-Myers Squibb has unveiled pooled five-year efficacy and safety results for its blockbuster immunotherapy Opdivo (nivolumab) drawn from two Phase …

News
tony-coles_0

Tony Coles appointed to Pfizer Spinout Cerevel as CEO

September 10, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cerevel, Pfizer, pharma

Cerevel Therapeutics, a pharmaceutical company dedicated to treating neurological diseases, has appointed renowned biotechnology leader Tony Coles as Chief Executive …

Appointment
merck-keytruda

MSD’s Keytruda approved for first-line lung cancer use on NHS Scotland

September 10, 2019
Manufacturing and Production, Sales and Marketing Cancer, MSD, SMC, Scotland, keytruda, lung cancer, pharma

MSD and lung cancer patients will be celebrating the news that the pharma giant’s immunotherapy Keytruda (pembrolizumab) has been accepted …

News
boehringer_biberach_germany_copy

Boehringer’s Ofev scores first-of-its-kind FDA approval in rare lung disease

September 10, 2019
Manufacturing and Production, Sales and Marketing Boehringer Ingelheim, FDA, US, lungs, ofev, pharma, rare disease

Boehringer Ingelheim’s Ofev (nintedanib) capsules have now secured marketing authorisation in the US, it has emerged, for the treatment of …

News
lilly_entrance_web

Lilly’s LOXO-292 shrinks tumours in lung cancer trial

September 9, 2019
Research and Development, Sales and Marketing Cancer, Eli Lilly, lung cancer, pharma

Eli Lilly has announced its experimental cancer drug LOXO-292, acquired in January, shrank tumours in almost 70% of advanced lung …

News
shutterstock

Age affects efficacy of immunotherapy treatments in breast cancer patients

September 9, 2019
Research and Development, Sales and Marketing Cancer, breast cancer, pharma

Recent clinical trial data has shown that immune checkpoints blockade (ICB) therapy, designed to unleash a patient’s immune system to …

News
trump-fda

Trump’s FDA: Is the US regulator being steered by the President?

September 9, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Trump, US, drug safety, pharma

FDA activity has fallen under Donald Trump, with the number of warning letters issued by the regulator dropping by a …

Feature
novartis_side_building

4.5-year data confirms long-term efficacy of Novartis’ Aimovig in episodic migraine

September 9, 2019
Research and Development, Sales and Marketing Aimovig, Novartis, migraine, pharma

Novartis has lifted the curtain on interim data from the 4.5-year mark of a five-year open-label treatment period (OLTP) investigating …

News

AstraZeneca’s Imfinzi combo tops chemotherapy in treatment-naive advanced lung cancer

September 9, 2019
Sales and Marketing AstraZeneca, Cancer, Imfinzi, lung cancer, pharma

AstraZeneca has unveiled new Phase 3 data for its immunotherapy Imfinzi (durvalumab), showing that it achieved its primary endpoint when …

News

Roche celebrates European approval of Tecentriq combo in first-line lung cancer

September 6, 2019
Medical Communications, Sales and Marketing Cancer, Europe, Roche, lung cancer, pharma, tecentriq

Roche has confirmed that its immunotherapy Tecentriq (atezolizumab) has been approved in Europe in combination with chemotherapy (carboplatin and etoposide) …

News
novartis_window

Novartis’ Lucentis secures European approval for infants with rare eye disease

September 6, 2019
Medical Communications, Sales and Marketing Europe, Lucentis, Novartis, eye disease, pharma

Novartis has made the surprise announcement that its VEGF inhibitor Lucentis (ranibizumab) has been awarded marketing authorisation from the European …

News

Experimental Novartis drug secures FDA Breathrough designation for rare lung cancer

September 6, 2019
Medical Communications, Sales and Marketing Cancer, Novartis, capmatinib, lung cancer, pharma

Novartis is celebrating the acceptance of its experimental cancer drug capmatinib by the FDA onto an accelerated review pathway, securing …

News
shutterstock_57369385

View of pharma industry sinks to new low in US, poll reveals

September 6, 2019
Medical Communications US, pharma

The public have always been reticent with their trust in the pharmaceutical industry, but that trust has hit an all-time …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026